Previous 10 | Next 10 |
2024-02-15 18:39:09 ET Pacific Biosciences of California, Inc. (PACB) Q4 2023 Earnings Conference Call February 15, 2024 05:00 PM ET Company Participants Todd Friedman - Senior Director, Investor Relations Christian Henry - President & Chief Executive Officer ...
2024-02-15 16:10:07 ET More on Pacific Biosciences of California Why Is Pacific Biosciences' Price Action So Bad? (Downgrade) Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth Pacific Biosciences' Revio And Onso Lead Looks Priced In For N...
PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results PR Newswire MENLO PARK, Calif. , Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023. ...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
2024-02-14 17:35:58 ET Major earnings expected after the bell on Thursday include: Roku ( ROKU ) Coinbase Global ( COIN ) Applied Materials ( AMAT ) The Trade Desk ( TTD ) DraftKings ( DKNG ) Read the full article on Seeking Alpha For ...
Experiential Marketing Firm VOLO Events Agency Wins Best Event Technology Award for PacBio Product Launch PR Newswire ATLANTA , Feb. 13, 2024 /PRNewswire/ -- VOLO Events Agency (VOLO), a leading producer of experiential marketing and live events for global br...
2024-02-12 13:06:08 ET Summary PacBio has reported strong financial performance, with a 113% growth in Q4 revenue and a 56% growth for the year. The launch of the Revio and Onso products has contributed to PacBio's growth and expansion in the genomic research market. However, ...
2024-02-08 10:03:39 ET Summary PacBio's financials for 2023 show significant growth, with revenue more than doubling in Q4 and a 56% increase in annual revenue compared to the previous year. The company's product innovations, such as the Revio system and Onso sequencer, have drive...
PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale PR Newswire New Library Preparation Solutions Offer Never Before Achieved Scale for the Revio™ Sequencing System MENLO PARK, Calif. , ...
PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024 PR Newswire MENLO PARK, Calif. , Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 fin...
News, Short Squeeze, Breakout and More Instantly...
Pacific Biosciences of California Inc. Company Name:
PACB Stock Symbol:
NASDAQ Market:
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases PR Newswire Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ...
2024-05-13 14:15:02 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for PACB on May 13, 2024 12:08PM ET. The previous analyst recommendation was Equal-Weight. PACB was trading at $1.975 at issue of the analyst recommendation. The overall analyst consensus : ...
2024-05-13 14:00:03 ET Tejas Savant from Morgan Stanley issued a price target of $4.00 for PACB on 2024-05-13 12:08:00. The adjusted price target was set to $4.00. At the time of the announcement, PACB was trading at $1.975. The overall price target consensus is at $2.50...